Executive Editor, Commercial/R&D
+26 year(s) experience
Alex has held a variety of editorial positions of increasing seniority on Scrip since joining the publication as a science reporter in 1998. Currently, she heads up the European editorial team coverage of commercial and R&D developments for Scrip, Pink Sheet and In Vivo, while also writing news, analysis and features for the publications.
Over the years, Alex has covered breakthroughs in R&D in a range of therapeutic areas, including infectious diseases, cardiology and cancer, and she enjoys interviewing key industry players and opinion leaders. Alex also has a keen interest in medical history, and a degree in Biochemistry and Microbiology.
On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.
Topic Influenza Virus
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class.
01 Aug 2017
27 Jun 2017